Sylvamo Expects 2Q23 Adjusted EBITDA Of $115M-$125M

Second Quarter Outlook We expect adjusted EBITDA to be $115 million to $125 million Compared to the first quarter: Price and mix are expected to decrease by $45

Second Quarter Outlook

  • We expect adjusted EBITDA to be $115 million to $125 million
  • Compared to the first quarter:
    • Price and mix are expected to decrease by $45 million to $50 million, reflecting the realization of prior price decreases for pulp in all regions and paper in Europe as well as less favorable product mix
    • Volume is projected to improve by $10 million to $15 million, with seasonally stronger volume in Latin America
    • Operations and costs are expected to increase by $10 million to $15 million primarily due to unabsorbed fixed costs
    • Input and transportation costs are projected to improve by $15 million to $20 million, with favorable trends in energy and chemicals
    • Total planned maintenance outage expenses are expected to increase by $59 million, with two-thirds of 2023 planned maintenance outage costs scheduled for the second quarter
Total
0
Shares
Related Posts
Read More

Centessa Pharmaceuticals To Present Additional Data From Open-Label Extension Of Phase 2a Study Of SerpinPC For Hemophilia At The 16th Annual Congress Of The European Association For Haemophilia And Allied Disorders On February 10, 2023

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present

CNTA